Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 3/2017

01-06-2017 | Kidney and Bone (S Moe and I Salusky, Section Editors)

What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease

Authors: Matthew R. Allen, Mohammad W. Aref

Published in: Current Osteoporosis Reports | Issue 3/2017

Login to get access

Abstract

Purpose of Review

Bisphosphonates (BPs) have long been the gold-standard anti-remodeling treatment for numerous metabolic bone diseases. Since these drugs are excreted unmetabolized through the kidney, they are not recommended for individuals with compromised kidney function due to concerns of kidney and bone toxicity. The goal of this paper is to summarize the preclinical BP work in models of kidney disease with particular focus on the bone, kidney, and vasculature.

Recent Findings

Summative data exists showing positive effects on bone and vascular calcifications with minimal evidence for bone or kidney toxicity in animal models.

Summary

Preclinical data suggest it may be worthwhile to take a step back and reconsider the use of bisphosphonates to lessen skeletal/vascular complications associated with compromised kidney function.
Literature
1.
2.
Troehler U, Bonjour J-P, Fleisch H. Renal secretion of diphosphonates in rats. Kidney Int. 1975;8:6–13.CrossRefPubMed
3.
4.
Tamura K, Suzuki Y, Matsushita M, Fujii H, Miyaura C, Aizawa S, et al. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol. 2007;558:159–66.CrossRefPubMed
5.
• Moe SM, Chen NX, Newman CL, Gattone II VH, Organ JM, Chen X, et al. A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res. 2014;29:902–10. One of the few studies to examine effects of bisphosphonates on bone remodeling and mechanics in animals with compromised kidney function. CrossRefPubMedPubMedCentral
6.
Price PA, Roublick AM, Williamson MK. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int. 2006;70:1577–83.CrossRefPubMed
7.
Ebetino FH, Hogan A-ML, Sun S, Tsoumpra MK, Duan X, Triffitt JT, et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 2011;49:20–33.CrossRefPubMed
8.
Russell RGG, Watts N, Ebetino FH, Rogers M. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733–59.CrossRefPubMed
9.
Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49:34–41.CrossRefPubMed
10.
Allen MR. Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment. Expert Opin Drug Metab Toxicol. 2008;4:1371–8.CrossRefPubMed
11.
12.
Lin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos. 1992;20:473–8.PubMed
13.
Usui T, Watanabe T, Higuchi S. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs. Drug Metab Dispos. 1995;23:1214–9.PubMed
14.
Plotkin L, Weinstein R, Parfitt A, Roberson P, Manolagas S, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363–74.CrossRefPubMedPubMedCentral
15.
Plotkin L, Manolagas S, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone. 2006;39:443–52.CrossRefPubMed
16.
Masarachia P, Weinreb M, Balena R. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone. 1996;19:281–90.CrossRefPubMed
17.
Kimmel D. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007;86:1022.CrossRefPubMed
18.
Fuchs R, Phipps R. Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Min Res. 2008;23:1689–97.CrossRef
19.
Troehler U, Bonjour JP, Fleisch H. Renal transport of bisphosphonates: accumulation by renal cortical slices enhanced by calcium phosphate ions. J Lab Clin Med. 1985;106:23–9.PubMed
20.
Pfister T, Atzpodien E, Bohrmann B, Bauss F. Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol. 2005;97:374–81.CrossRefPubMed
21.
• Bergner R, Siegrist B, Kränzlin B, Gretz N, Faust H, Pfister T. Determination of renal tissue ibandronate levels in rats with normal and mildly impaired renal function. J Pharmacol Toxicol Methods. 2013;68:225–30. Excellent study that examines renal handing of bisphosphonates in animals with compromised kidney function. CrossRefPubMed
22.
Lühe A, Künkele K-P, Haiker M, Schad K, Zihlmann C, Bauss F, et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol in Vitro. 2008;22:899–909.CrossRefPubMed
23.
Alden CL, Parker RD, Eastman DF. Development of an acute model for the study of chloromethanediphosphonate nephrotoxicity. Toxicol Pathol. 1989;17:27–32.PubMed
24.
Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology. 2003;191:159–67.CrossRefPubMed
25.
Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacology & toxicology. 1997;80:225–30.CrossRef
26.
Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–53.CrossRefPubMed
27.
Malluche HH, Porter DS, Monier-Faugere M-C, Mawad H, Pienkowski D. Differences in bone quality in low- and high-turnover renal osteodystrophy. J Am Soc Nephrol. 2012;23:525–32.CrossRefPubMedPubMedCentral
28.
Andress DL, Maloney NA, Endres DB, Sherrard DJ. Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. J Bone Miner Res. 1986;1:391–8.CrossRefPubMed
29.
Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. Standardized nomenclature, symbols, and units for bone histomorphometry. J Bone Miner Res. 2013;28:2–17.CrossRefPubMedPubMedCentral
30.
Recker R, Kimmel D, Dempster D, Weinstein R, Wronski T, Burr DB. Issues in Histomorphometry. Bone. 2011;49:955–64.
31.
• Lomashvili KA, Monier-Faugere M-C, Wang X, Malluche HH, O'Neill WC. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int. 2009;75:617–25. One of the few studies to examine effects of bisphosphonates on vascular calcification in animals with compromised kidney function. CrossRefPubMedPubMedCentral
32.
Jokihaara J, Pörsti IH, Kööbi P, Jolma PM, Mustonen JT, Saha HHT, et al. Treatment of experimental renal osteodystrophy with pamidronate. Kidney Int. 2008;74:319–27.CrossRefPubMed
33.
Geng Z, Monier-Faugere MC, Bauss F, Malluche HH. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol. 2000;54:45–53.PubMed
34.
Allen MR, Chen NX, Gattone VH, Chen X, Carr AJ, LeBlanc P, et al. Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int. 2012;24:1471–81.CrossRefPubMedPubMedCentral
35.
Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somoza J, Friedman S, et al. Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Nueronal Interact. 2005;5:174–81.
36.
Newman CL, Chen NX, Smith E, Smith M, Brown D, Moe SM, et al. Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions. Bone. 2015;77:50–6.CrossRefPubMedPubMedCentral
37.
38.
Newman CL, Moe SM, Chen NX, Hammond MA, Wallace JM, Nyman JS, et al. Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease. PLoS One. 2014;9:e99262.CrossRefPubMedPubMedCentral
39.
Allen MR, Newman CL, Chen N, Granke M, Nyman JS, Moe SM. Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease. Osteoporos Int. 2014;26:977–85.CrossRefPubMedPubMedCentral
40.
Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don’t know. Bone. 2011;49:56–65.CrossRefPubMed
41.
Fischer D-C, Jensen C, Rahn A, Salewski B, Kundt G, Behets GJ, et al. Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function. Pediatr Nephrol. 2010;26:111–7.CrossRefPubMed
42.
Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19:213–6.CrossRefPubMed
43.
Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001;21:817–24.CrossRefPubMed
Metadata
Title
What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease
Authors
Matthew R. Allen
Mohammad W. Aref
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 3/2017
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-017-0361-4

Other articles of this Issue 3/2017

Current Osteoporosis Reports 3/2017 Go to the issue

Kidney and Bone (S Moe and I Salusky, Section Editors)

Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder

Cancer-induced Musculoskeletal Diseases (M Reagan and E Keller, Section Editors)

MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells

Rare Bone Diseases (C Langman and E Shore, Section Editors)

Hereditary Multiple Exostoses: New Insights into Pathogenesis, Clinical Complications, and Potential Treatments

Muscle and Bone (L Bonewald and M Hamrick, Section Editors)

The Role of the Molecular Clock in Skeletal Muscle and What It Is Teaching Us About Muscle-Bone Crosstalk

Osteoimmunology (M Nakamura and M Humphrey, Section Editors)

TNF and Bone Remodeling

Kidney and Bone (S Moe and I Salusky, Section Editors)

Calcium Balance in Chronic Kidney Disease